D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
NBSE holding history
NeuBase Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBSE overviewAll 13F holders of NBSEFull Q2 2026 holdings
- Shares (Q2 2022)
- 0
- Sold out in Q2 2022
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 4
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2022 | 0 | $0 | 0.0% | −37,416−100.0% | Sold out | Holders |
| Q1 2022 | 37,416 | $70.0K | <0.1% | +37,416 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −44,801−100.0% | Sold out | Holders |
| Q3 2021 | 44,801 | $162.0K | <0.1% | −13,173−22.7% | Reduced | Holders |
| Q2 2021 | 57,974 | $278.0K | <0.1% | −38,265−39.8% | Reduced | Holders |
| Q1 2021 | 96,239 | $711.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.